Novel adjunctive therapy for drug resistant Gram-negative pathogens
Novel adjunctive therapy for drug resistant Gram-negative pathogens
批准号:
8840535
负责人:
Robert Ernest William Hancock
金额:
$26.31万
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-06-18 至 2017-05-31
关键词:
AcinetobacterAcinetobacter baumanniiAddressAdjuvant TherapyAdultAnimal ModelAntibiotic ResistanceAntibiotic TherapyAntibioticsAntiviral resistanceBacteriaBiological AssayBritish ColumbiaBurkholderiaCAP18 lipopolysaccharide-binding proteinCampylobacterCanadaCellsCessation of lifeChemotherapy-Oncologic ProcedureChildhoodClinicClinicalClinical TrialsCollaborationsCommunicable DiseasesComplexComputing MethodologiesDataDental ResearchDevelopmentDissociationDrug resistanceEnterobacterEscherichia coli O157ExplosionGenesGenetic TranscriptionGoalsGram-Negative BacteriaGram-Negative Bacterial InfectionsGrowthHost DefenseHumanIn VitroInfectionInsectaInstitutesKlebsiellaKlebsiella pneumonia bacteriumLife ExpectancyListeria monocytogenesLungMedicineMembraneMethodsMicrobial BiofilmsModelingMulti-Drug ResistanceOrgan TransplantationOrganismPenicillinsPeptide HydrolasesPeptidesPharmaceutical PreparationsPhasePlantsPolymyxinsPropertyPseudomonasPseudomonas aeruginosaPublic HealthQuantitative Structure-Activity RelationshipResearchResistanceSalmonellaStagingStructureSystemTestingTexasTherapeuticTimeTopical AntibioticToxic effectTrauma ResearchTwin Multiple BirthUniversitiesVariantantimicrobialantimicrobial peptidebasecell motilitydesignin vivomouse modelnatural antimicrobialnovelnovel strategiesnovel therapeuticspathogenpreclinical studypredictive modelingpreventquorum sensingscreeningstemsurgical researchsynthetic peptideuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
It is becoming increasingly recognized that the therapy of infectious diseases is facing twin threats. On the
one hand antibiotic and antiviral resistance is rising rapidly; on the other there are relatively few novel
compounds under development or entering the clinic. One promising set of compounds are the cationic host
defence (antimicrobial) peptides, that collectively have anti-biofilm, antimicrobial and immunomodulatory
activities and are naturally produced by virtually all complex organisms ranging from plants and insects to
humans as a major component of their innate defences against infection. Our research has been instrumental
in delivering, to clinical trials, both topical antimicrobials and selectively immunomodulatory innate defence
regulator (IDR) peptides; however these trials did not explore the full potential of these molecules. Recently we
demonstrated that some of these peptides suppress the formation of biofilms by a number of serious Gram
negative bacterial infections. Here we are pursuing this strategy as an adjunct to conventional antibiotic
therapy. It is particularly relevant since bacteria causing infections often (60%) grow as biofilms that are
specialized colonial structures that are highly resistant to conventional antibiotics.
The objective here is this to suppress biofilm infection by highly resistant and dangerous pathogens, making
these infections more susceptible to conventional antibiotics. Our major broad long term objective is thus to
create badly needed new approaches to treating infections to overcome antibiotic resistance in the face of a
dearth in new antibiotic discovery.
Our Specific Aims, in large part based on preliminary data, are (1) identify peptides with optimized activities
that are smaller and resistant to proteases, (2) test synergy with a variety of conventional antibiotics against
organisms in the biofilm state, (3) understand the mechanism(s) of anti-biofilm activity and (4) characterize
their activity in realistic models of infection.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Transcriptomics to define biomarkers of neonatal vaccine immunogenicity
-
批准号:10063823
-
项目类别:
-
资助金额:$25.27万
-
财政年份:2016
-
负责人:Robert Ernest William Hancock
-
依托单位:
Transcriptomics to define biomarkers of neonatal vaccine immunogenicity
-
批准号:9245973
-
项目类别:
-
资助金额:$22.59万
-
财政年份:2016
-
负责人:Robert Ernest William Hancock
-
依托单位:
Novel adjunctive therapy for drug resistant Gram-negative pathogens
-
批准号:8491975
-
项目类别:
-
资助金额:$12.63万
-
财政年份:2012
-
负责人:Robert Ernest William Hancock
-
依托单位:
Novel adjunctive therapy for drug resistant Gram-negative pathogens
-
批准号:8267449
-
项目类别:
-
资助金额:$17.02万
-
财政年份:2012
-
负责人:Robert Ernest William Hancock
-
依托单位:
海外基金